[
  {
    "ts": null,
    "headline": "Tracking Dan Loeb's Third Point Portfolio - Q2 2025 Update",
    "summary": "Third Point's Q2 2025 13F portfolio rose to $7.62B, with increased concentration in top holdings. Read more about the portfolio here.",
    "url": "https://finnhub.io/api/news?id=71bbfbe10a9e018a8249ca1282de53aa18a6fac5214ffecc344e5f68785b67f5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757364764,
      "headline": "Tracking Dan Loeb's Third Point Portfolio - Q2 2025 Update",
      "id": 136673616,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "DHR",
      "source": "SeekingAlpha",
      "summary": "Third Point's Q2 2025 13F portfolio rose to $7.62B, with increased concentration in top holdings. Read more about the portfolio here.",
      "url": "https://finnhub.io/api/news?id=71bbfbe10a9e018a8249ca1282de53aa18a6fac5214ffecc344e5f68785b67f5"
    }
  },
  {
    "ts": null,
    "headline": "Radioimmunoassay Market Research Report 2025-2033 | Broader Applications Across Developed and Emerging Markets Accelerate Adoption of RIA in Diagnostics and Research",
    "summary": "The global Radioimmunoassay (RIA) market is set to expand from $710 million in 2024 to $1.12 billion by 2033, growing at a CAGR of 5.21%. Key drivers include advancements in endocrinology, oncology, infectious disease research, and wider application of RIA in both advanced and emerging markets. The market is propelled by technological improvements in RIA kits, increased demand for precise disease diagnosis, and growing pharmaceutical applications. However, it faces competition from non-radioacti",
    "url": "https://finnhub.io/api/news?id=36895c2891e2658bcd6da50c4802aac9ef964598c9499e8ca1cc483a4d3f47f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757341500,
      "headline": "Radioimmunoassay Market Research Report 2025-2033 | Broader Applications Across Developed and Emerging Markets Accelerate Adoption of RIA in Diagnostics and Research",
      "id": 136674547,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "The global Radioimmunoassay (RIA) market is set to expand from $710 million in 2024 to $1.12 billion by 2033, growing at a CAGR of 5.21%. Key drivers include advancements in endocrinology, oncology, infectious disease research, and wider application of RIA in both advanced and emerging markets. The market is propelled by technological improvements in RIA kits, increased demand for precise disease diagnosis, and growing pharmaceutical applications. However, it faces competition from non-radioacti",
      "url": "https://finnhub.io/api/news?id=36895c2891e2658bcd6da50c4802aac9ef964598c9499e8ca1cc483a4d3f47f4"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks We’re Skeptical Of",
    "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 1.4% gain for healthcare stocks has fallen short of the S&P 500’s 15.5% rise.",
    "url": "https://finnhub.io/api/news?id=9ce79056407fbad05bbdffd225aee6273ba43a38c47cfd9c12bf909589d04ea8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757309631,
      "headline": "3 Healthcare Stocks We’re Skeptical Of",
      "id": 136669387,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 1.4% gain for healthcare stocks has fallen short of the S&P 500’s 15.5% rise.",
      "url": "https://finnhub.io/api/news?id=9ce79056407fbad05bbdffd225aee6273ba43a38c47cfd9c12bf909589d04ea8"
    }
  }
]